Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 6NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NIH × gallium Ga 68 dotatate × Clear all
NCT06479811 2026-04-28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
120 enrolled
CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡